Abstract: The present invention applies to a deuterated derivative of 3,3?-diselenodipropionic acid (D-DSePA), an organo-selenium compound and method of synthesis thereof. The invention also provides the method including D-DSePA for the inhibition of the proliferation of human non-small cell lung carcinoma (NSCLC) cells. This compound inhibits the proliferation of A549, H1975 and H3122 cells of NSCLC origin at a much lower concentration than that needed to inhibit the growth of non-cancerous lung fibroblast cells (WI-38 and WI-26 VA4). Further, D-DSePA exhibits additive effect in A549 lung cancer cells while protecting non-cancerous WI38 cells from radiotoxicity.

Abstract: The present invention describes the method of using a synthetic organoselenium compound, DSePA for management of non-small cell lung carcinoma (NSCLC) and chronic myelogenous leukemia (CML). The method comprises administering DSePA orally at a dosage of 1 mg/Kg body weight daily for inhibiting the growth of A549 (representative of NSCLC) and K562 (representative of CML) tumor in mice models. Additionally, the said compound also inhibits the proliferation of other cancer cells of NSCLC (HOP-62 and H460), breast (MDA-MB-231), white blood cells (JURKAT and U-937), oral (SCC-40), colon (HT-29), kidney (A498) and cervix (SiHA) origins in cellular models at a much lower concentration than that needed to inhibit the growth of normal cells.